247 related articles for article (PubMed ID: 29505900)
21. Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.
Okumura N; Sonobe M; Okabe K; Nakamura H; Kataoka M; Yamashita M; Nakata M; Kataoka K; Yamashita Y; Soh J; Yoshioka H; Hotta K; Matsuo K; Sakamoto J; Toyooka S; Date H
Int J Clin Oncol; 2017 Apr; 22(2):274-282. PubMed ID: 27921177
[TBL] [Abstract][Full Text] [Related]
22. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
23. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
24. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.
Socinski MA; Schell MJ; Peterman A; Bakri K; Yates S; Gitten R; Unger P; Lee J; Lee JH; Tynan M; Moore M; Kies MS
J Clin Oncol; 2002 Mar; 20(5):1335-43. PubMed ID: 11870177
[TBL] [Abstract][Full Text] [Related]
25. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
Uramoto H; Nakanishi R; Nagashima A; Uchiyama A; Inoue M; Osaki T; Yoshimatsu T; Sakata H; Nakanishi K; Yasumoto K
Anticancer Res; 2010 Nov; 30(11):4695-9. PubMed ID: 21115926
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
27. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
Perry MC; Kohman LJ; Bonner JA; Gu L; Wang X; Vokes EE; Green MR
Clin Lung Cancer; 2007 Jan; 8(4):268-72. PubMed ID: 17311692
[TBL] [Abstract][Full Text] [Related]
28. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217
[TBL] [Abstract][Full Text] [Related]
29. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
Felip E; Rosell R; Maestre JA; Rodríguez-Paniagua JM; Morán T; Astudillo J; Alonso G; Borro JM; González-Larriba JL; Torres A; Camps C; Guijarro R; Isla D; Aguiló R; Alberola V; Padilla J; Sánchez-Palencia A; Sánchez JJ; Hermosilla E; Massuti B;
J Clin Oncol; 2010 Jul; 28(19):3138-45. PubMed ID: 20516435
[TBL] [Abstract][Full Text] [Related]
30. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
Tsuchiya T; Kamohara R; Muraoka M; Nagayasu T; Saeki S; Takenoyama M; Suzuki M; Inada K; Tokunaga S; Hayashi T; Urabe S; Koga T; Akamine S; Sugio K
BMC Cancer; 2020 Dec; 20(1):1192. PubMed ID: 33276755
[TBL] [Abstract][Full Text] [Related]
31. Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.
Ahmed S; Birnbaum AE; Safran HP; Dipetrillo TA; Aswad BI; Ready NE; Ng T
J Thorac Oncol; 2011 Aug; 6(8):1432-4. PubMed ID: 21847062
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M
J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).
Kosmidis P; Mylonakis N; Skarlos D; Samantas E; Dimopoulos M; Papadimitriou C; Kalophonos C; Pavlidis N; Nikolaidis C; Papaconstantinou C; Fountzilas G
Ann Oncol; 2000 Jul; 11(7):799-805. PubMed ID: 10997806
[TBL] [Abstract][Full Text] [Related]
34. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
35. Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer: FAST-nab.
Saji H; Marushima H; Miyazawa T; Sakai H; Kimura H; Kurimoto N; Nakamura H
Anticancer Drugs; 2017 Aug; 28(7):795-800. PubMed ID: 28538017
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
[TBL] [Abstract][Full Text] [Related]
37. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
Schmid-Bindert G; Engel-Riedel W; Reck M; Schuette W; Stöhlmacher J; Fischer JR; Mazières J; Chouaid C; Wolf M; Vinolas N; Soldatenkova V; Ripoche V; Nguyen T; Visseren-Grul C
Lung Cancer; 2015 Dec; 90(3):397-404. PubMed ID: 26791798
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
Kuyama S; Ochi N; Bessho A; Hotta K; Ikeda G; Kishino D; Kubo T; Harada D; Fujimoto N; Nakanishi M; Umeno T; Okada T; Chikamori K; Yamagishi T; Ohashi K; Ichihara E; Takigawa N; Tanimoto M; Kiura K
Lung Cancer; 2017 Oct; 112():188-194. PubMed ID: 29191594
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Langer CJ; O'Byrne KJ; Socinski MA; Mikhailov SM; Leśniewski-Kmak K; Smakal M; Ciuleanu TE; Orlov SV; Dediu M; Heigener D; Eisenfeld AJ; Sandalic L; Oldham FB; Singer JW; Ross HJ
J Thorac Oncol; 2008 Jun; 3(6):623-30. PubMed ID: 18520802
[TBL] [Abstract][Full Text] [Related]
40. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
